Biohaven says FDA accepts NDA resubmission for VYGLXIA in spinocerebellar ataxia

Biohaven announced the FDA accepted its resubmission of the New Drug Application for VYGLXIA (troriluzole) in spinocerebellar ataxia.

Detected & updated continuously · Source: Nebula

Story subjects

Biohaven Ltd.Food and Drug Administration

Track sentiment and mindshare across stocks and crypto in Nebula.